Managing chronic subdural hematoma in aging populations presents formidable surgical and pharmacological challenges. Clinicians frequently encounter frail patients who require life-sustaining antithrombotic medications for cardiovascular or cerebrovascular comorbidities. Consequently, surgeons must navigate the delicate balance between preventing thromboembolic events and minimizing hemorrhagic complications. Twist-drill craniostomy with subdural drainage offers a minimally invasive bedside solution for evacuating these collections. However, chronic subdural hematoma recurrence remains a pervasive complication that often necessitates repeat surgical evacuation. Until recently, clinical teams debated whether baseline antithrombotic therapy directly drives surgical reinterventions. A major multi-year study now provides crucial clarification regarding these clinical risks. Furthermore, the findings illuminate how specific antithrombotic classes distinctly influence surgical failure rates.

Predicting Chronic Subdural Hematoma Recurrence After Twist-Drill Craniostomy

A team of neurosurgeons conducted a large retrospective cohort investigation at a tertiary referral center between 2018 and 2025. They evaluated 924 consecutive adult patients who underwent first-time twist-drill craniostomy with closed-system subdural drainage. To establish clear baseline exposures, investigators categorized medications into five distinct cohorts. Specifically, these groups comprised patients taking no antithrombotics, antiplatelet monotherapy, vitamin K antagonists, direct oral anticoagulants, or dual antithrombotic therapy.

Furthermore, the hospital team implemented a standardized perioperative reversal protocol upon hospital admission. They discontinued all antithrombotic drugs immediately and administered appropriate reversal agents before drilling. The surgical team subsequently maintained closed subdural drainage to encourage brain re-expansion. The primary endpoint measured reoperation for recurrent or residual ipsilateral collections within three months following the index procedure. Notably, 279 out of 924 patients required repeat surgery, establishing an overall reoperation rate of 30.2 percent. This high recurrence frequency underscores the substantial clinical burden that chronic subdural collections impose on neurosurgical services. Therefore, identifying baseline predictors of treatment failure represents an urgent clinical priority for acute care teams.

Evaluating Reoperation Rates Across Antithrombotic Regimens

When researchers stratified the patient cohort by baseline medication exposure, marked disparities in surgical outcomes quickly emerged. Specifically, patients without any prior antithrombotic exposure demonstrated a baseline reoperation rate of 25.6 percent. In comparison, patients receiving antiplatelet monotherapy experienced a slightly higher reoperation rate of 29.3 percent.

However, patients taking systemic anticoagulants faced substantially higher rates of surgical failure. Individuals receiving vitamin K antagonists required reoperation in 32.2 percent of cases. Similarly, patients on direct oral anticoagulants demonstrated an elevated reoperation rate of 42.4 percent. Most strikingly, patients receiving dual antithrombotic therapy experienced a reoperation rate of 62.5 percent. These raw figures illustrate a dramatic gradient of surgical risk. Consequently, clinicians must recognize that not all antithrombotic regimens carry equivalent postoperative hazards. While single antiplatelet therapy produced only modest increases in repeat procedures, anticoagulant regimens caused dramatic surges in reoperation. Furthermore, the combination of multiple antithrombotic agents amplified these hazards dramatically. Thus, medication history provides an immediate risk-stratification tool during initial emergency evaluation.

Multivariable Analysis and the Unique Impact of Anticoagulants

To eliminate confounding variables, the authors performed robust multivariable logistic regression modeling. They adjusted the statistical calculations for patient age, biological sex, hematoma laterality, and the presence of organized hematoma membranes. After comprehensive adjustment, vitamin K antagonists maintained an independent association with surgical failure, yielding an odds ratio of 2.01.

Similarly, direct oral anticoagulants independently elevated the odds of reoperation, demonstrating an adjusted odds ratio of 1.68. Dual antithrombotic regimens exhibited the most alarming correlation, generating an adjusted odds ratio of 4.56. In stark contrast, antiplatelet monotherapy did not independently predict surgical recurrence after multivariable adjustment. These statistical adjustments confirm that baseline anticoagulation independently compromises primary surgical success. Furthermore, older age and architectural membranes cannot solely explain the observed failures. Because direct oral anticoagulants and vitamin K antagonists disrupt fundamental clotting cascades, they likely impair microscopic hemostasis within the subdural space. Consequently, surgeons must realize that reversing circulating drugs does not completely eliminate rebleeding hazards. Ultimately, clinicians should maintain heightened vigilance whenever operating on anticoagulated patients.

Mechanisms Driving Hematoma Persistence and Rebleeding

Understanding the pathophysiological mechanisms underlying hematoma expansion clarifies why anticoagulants provoke recurrent disease. Chronic subdural hematomas originate when fragile bridging veins tear, creating a fluid collection within the dural border cell layer. Subsequently, the body forms an outer neo-membrane rich in fragile, fenestrated capillaries. These abnormal microvessels continuously leak fluid, plasma proteins, and red blood cells into the subdural space.

Moreover, local hyperfibrinolysis and persistent inflammatory cascades continually degrade developing clots. When patients receive systemic anticoagulation, circulating clotting factors remain compromised even after standard reversal attempts. As a result, microvascular oozing from the vascularized neo-membrane persists after twist-drill evacuation. In contrast, single antiplatelet agents primarily impair platelet aggregation without paralyzing downstream thrombin generation. Therefore, sufficient fibrin formation can still occur along the capsular surface, preventing catastrophic refilling. Dual antithrombotic therapy, however, cripples both primary platelet plug formation and secondary enzymatic coagulation. Consequently, recurrent hemorrhage overwhelms passive drainage systems, leading to rapid symptomatic reaccumulation.

Clinical Implications and Postoperative Surveillance Strategies

These findings carry direct practical implications for neurosurgeons, neurologists, and intensivists managing subdural collections. First, clinicians should identify patients receiving anticoagulants or dual antithrombotics as ultra-high-risk individuals immediately upon admission. Because these cohorts experience reoperation rates exceeding forty to sixty percent, standard follow-up protocols may prove insufficient.

Instead, surgical teams should implement intensive clinical monitoring and scheduled neuroimaging before hospital discharge. Furthermore, bedside twist-drill craniostomy might require supplemental therapeutic strategies in this vulnerable population. For instance, neurosurgeons could consider middle meningeal artery embolization as an adjunctive treatment. By devascularizing the hypervascular outer membrane, embolization significantly reduces microvascular leakage and suppresses recurrence. Additionally, multidisciplinary teams must establish customized recovery pathways for anticoagulated individuals. Rather than relying on passive gravity drains alone, teams might explore extended drainage duration or selective irrigation techniques. Ultimately, tailored postoperative surveillance ensures early detection of asymptomatic reaccumulation before catastrophic neurological deterioration occurs.

Balancing Hemostasis and Thromboprophylaxis in Geriatric Practice

Managing antithrombotic therapy following successful hematoma evacuation represents one of the most perilous dilemmas in modern geriatrics. Clinicians initially prescribe these potent medications to prevent disabling strokes, myocardial infarctions, or systemic thromboembolism. However, resuming therapy prematurely inevitably reignites the cascade of subdural rebleeding. Conversely, withholding antithrombotics indefinitely exposes medically frail patients to lethal ischemic events.

Therefore, physicians must engage in nuanced, patient-specific risk assessments before restarting antithrombotic medications. To optimize outcomes, cardiologists, neurologists, and neurosurgeons should collaborate closely to determine the optimal therapeutic window. Current consensus generally favors delaying oral anticoagulation for at least two to four weeks postoperatively. Moreover, clinicians must obtain follow-up cranial imaging to confirm complete hematoma resolution before medication reintroduction. In patients requiring lifelong anticoagulation, clinicians should actively re-evaluate the original indication. If feasible, clinicians should discontinue unnecessary antiplatelet co-medications to avoid high-risk dual therapy. By maintaining this disciplined, multidisciplinary equilibrium, medical teams protect cardiovascular function without jeopardizing neurosurgical recovery.

Frequently Asked Questions

Does antiplatelet therapy increase the need for reoperation after craniostomy?

Antiplatelet monotherapy does not independently elevate reoperation risk after twist-drill craniostomy. In multivariable models, patients taking aspirin or clopidogrel experienced recurrence rates comparable to unmedicated controls. Consequently, clinicians can manage antiplatelet-treated individuals with standard postoperative protocols, provided the surgical team temporarily holds the medication and maintains reliable subdural drainage.

Why does dual antithrombotic therapy create such high recurrence rates?

Dual antithrombotic therapy dramatically raises recurrence because it impairs both platelet aggregation and the coagulation cascade simultaneously. This combined physiological disruption prevents durable clot formation along fragile neocapillaries lining the hematoma membrane. Consequently, continuous microvascular leakage rapidly overwhelms the subdural space, leading to symptomatic refilling that requires urgent surgical revision.

How should surgical teams monitor high-risk patients following subdural drainage?

Surgical teams should establish rigorous follow-up pathways for patients receiving anticoagulants or dual antiplatelet regimens. Clinicians must perform serial neurological evaluations and scheduled cranial imaging before discharge. Furthermore, multidisciplinary teams should delay antithrombotic resumption until imaging confirms resolution, while considering adjunctive therapies like middle meningeal artery embolization to minimize failure.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Doria-Medina R et al. Antithrombotic therapy and recurrence requiring surgery after twist-drill craniostomy for first-time chronic subdural hematoma. Clin Neurol Neurosurg. 2026 Oct. doi: 10.1016/j.clineuro.2026.109570. PMID: 42424791.


2. Poon MTC, Rea C, Kolias AG, et al. Impact of antithrombotic agents on outcomes in patients requiring surgery for chronic subdural haematoma: a systematic review and meta-analysis. Br J Neurosurg. 2024;38(2):1-10.


3. Kerttula S, Luostarinen T, Raj R, et al. The effect of antithrombotic therapy on the recurrence and outcome of chronic subdural hematoma after burr-hole craniostomy in a population-based cohort. Acta Neurochir (Wien). 2022;164(10):2683-2691.